title: Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma.
abstract: Interleukin 6 (IL-6) is a major growth factor for myeloma cells and retinoids have been shown to inhibit expression of the interleukin 6 receptor (IL-6R). We performed a pilot study to assess the efficacy and tolerability of 13cis retinoic acid (13cRA) and dexamethasone (Dex), when added to interferon alpha (IFNalpha) as maintenance therapy post autologous stem cell transplantation. Between 90 and 120 days post stem cell transplantation, 33 patients were started on 13cRA 1 mg/kg p.o. daily for 14 days and Dex 40 mg p.o daily for 5 days every month. 13cRA was dose escalated by 0.5 mg/kg/month to 2 mg/kg. Seventeen patients had a persistent paraprotein post transplant. Overall, a response to therapy was observed in 11/17 (64%), with a complete response in 4/17 (23.5%) and a partial response (>/=50% paraprotein decline) in 7/17 (41%). With a median follow-up of 34.8 months, 22/33 (66%) demonstrated disease progression and 11/33 (33%) died. The median progression-free survival from diagnosis was 34.7 months. Although a decline in paraprotein was frequently observed on triple therapy, many patients discontinued therapy due to the side-effects of the IFNalpha. Future trials should be designed using 13cRA and Dex alone.
authors.affiliation: Department of Internal Medicine, Barnes-Jewish Hospital, Washington University School of Medicine, Saint Louis, MO 63110-1093, USA.
authors.forename: J
authors.initials: J
authors.lastname: Friedman
authors.forename: H
authors.initials: H
authors.lastname: Khoury
authors.forename: D
authors.initials: D
authors.lastname: Adkins
authors.forename: S
authors.initials: S
authors.lastname: Devine
authors.forename: B
authors.initials: B
authors.lastname: Nervi
authors.forename: T
authors.initials: T
authors.lastname: Edwards
authors.forename: J
authors.initials: J
authors.lastname: Dipersio
authors.forename: R
authors.initials: R
authors.lastname: Vij
mesh_terms: D000328:Adult; D000368:Aged; D003907:Dexamethasone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000097:blood; D015474:Isotretinoin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D010865:Pilot Projects; D019947:Receptors, Interleukin-6 / Q000097:blood; D014182:Transplantation, Autologous
chemical_list: D016898:Interferon-alpha; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D003907:Dexamethasone; D015474:Isotretinoin